{
  "symbol": "LLY",
  "year": 2022,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2712,
    "outlook_sentiment": 0.0841,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.5
  },
  "top_positive": [
    {
      "sent": "21 Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Short-term commercial paper borrowings March 31, 2022 $ ( 499.7 ) $ \u2014 $ ( 499.7 ) $ \u2014 $ ( 499.7 ) December 31, 2021 \u2014 \u2014 \u2014 \u2014 \u2014 Long-term debt, including current portion March 31, 2022 $ ( 16,009.1 ) $ \u2014 $ ( 15,798.9 ) $ \u2014 $ ( 15,798.9 ) December 31, 2021 ( 16,884.7 ) \u2014 ( 18,157.7 ) \u2014 ( 18,157.7 ) 22 Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2022 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other receivables $ 1.3 $ \u2014 $ 1.3 $ \u2014 $ 1.3 Other noncurrent assets 22.8 \u2014 22.8 \u2014 22.8 Other noncurrent liabilities ( 43.2 ) \u2014 ( 43.2 ) \u2014 ( 43.2 ) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 140.0 \u2014 140.0 \u2014 140.0 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 2.0 \u2014 2.0 \u2014 2.0 Other noncurrent assets 40.0 \u2014 40.0 \u2014 40.0 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 40.8 \u2014 40.8 \u2014 40.8 Foreign exchange contracts not designated as hedging instruments: Other receivables 38.8 \u2014 38.8 \u2014 38.8 Other current liabilities ( 45.8 ) \u2014 ( 45.8 ) \u2014 ( 45.8 ) Contingent consideration liability: Other noncurrent liabilities ( 70.0 ) \u2014 \u2014 ( 70.0 ) ( 70.0 ) December 31, 2021 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other receivables $ 4.8 $ \u2014 $ 4.8 $ \u2014 $ 4.8 Other noncurrent assets 78.3 \u2014 78.3 \u2014 78.3 Other noncurrent liabilities ( 7.6 ) \u2014 ( 7.6 ) \u2014 ( 7.6 ) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 49.2 \u2014 49.2 \u2014 49.2 Other noncurrent liabilities ( 31.7 ) \u2014 ( 31.7 ) \u2014 ( 31.7 ) Cross-currency interest rate contracts designated as net investment hedges: Other noncurrent assets 31.3 \u2014 31.3 \u2014 31.3 Other current liabilities ( 1.2 ) \u2014 ( 1.2 ) \u2014 ( 1.2 ) Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 33.2 \u2014 33.2 \u2014 33.2 Other noncurrent liabilities ( 1.3 ) \u2014 ( 1.3 ) \u2014 ( 1.3 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.9 \u2014 9.9 \u2014 9.9 Other current liabilities ( 35.3 ) \u2014 ( 35.3 ) \u2014 ( 35.3 ) Contingent consideration liabilities: Other noncurrent liabilities ( 70.5 ) \u2014 \u2014 ( 70.5 ) ( 70.5 ) 23 Risk-management instruments above are disclosed on a gross basis.",
      "score": 0.9933
    },
    {
      "sent": "20 Fair Value of Financial Instruments The following tables summarize certain fair value information at March\u00a031, 2022 and December\u00a031, 2021 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2022 Cash equivalents $ 1,104.1 $ 1,104.1 $ 1,095.0 $ 9.1 $ \u2014 $ 1,104.1 Short-term investments: U.S.",
      "score": 0.9842
    },
    {
      "sent": "25 Note 8: Retirement Benefits Net pension and retiree health benefit (income) cost included the following components: Defined Benefit Pension Plans Three Months Ended March 31, 2022 2021 Components of net periodic benefit cost: Service cost $ 89.1 $ 92.0 Interest cost 100.5 84.3 Expected return on plan assets ( 239.5 ) ( 238.0 ) Amortization of prior service cost 0.7 1.1 Recognized actuarial loss 87.0 121.8 Net periodic benefit cost $ 37.8 $ 61.2 Retiree Health Benefit Plans Three Months Ended March 31, 2022 2021 Components of net periodic benefit income: Service cost $ 11.2 $ 11.7 Interest cost 9.4 8.1 Expected return on plan assets ( 37.9 ) ( 36.6 ) Amortization of prior service benefit ( 13.7 ) ( 14.9 ) Recognized actuarial loss 0.2 0.8 Net periodic benefit income $ ( 30.8 ) $ ( 30.9 ) Note 9: Contingencies We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business.",
      "score": 0.9842
    }
  ],
  "top_negative": [
    {
      "sent": "threat and the global response thereto; \u2022 uncertainties related to our efforts to develop, manufacture, and distribute potential treatments for COVID-19; \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and outcome of acquisitions and business development transactions and related integration costs; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property; \u2022 changes in patent law or regulations related to data package exclusivity; \u2022 competitive developments affecting current products and our pipeline; \u2022 market uptake of recently launched products; \u2022 information technology system inadequacies, breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; \u2022 unexpected safety or efficacy concerns associated with our products; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions relating to our facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 regulatory changes or other developments; \u2022 regulatory actions regarding currently marketed products; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; \u2022 devaluations in foreign currency exchange rates, changes in interest rates, and inflation; \u2022 changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; \u2022 asset impairments and restructuring charges; \u2022 the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions; \u2022 changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and \u2022 regulatory compliance problems or government investigations.",
      "score": -0.5423
    },
    {
      "sent": "Revenue of Jardiance, a treatment for type 2 diabetes, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, regardless of left ventricular ejection fraction, increased 52 percent in the U.S.",
      "score": -0.9477
    },
    {
      "sent": "Revenue of Jardiance, a treatment for type 2 diabetes, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, regardless of left ventricular ejection fraction, increased 52 percent in the U.S.",
      "score": -0.9477
    },
    {
      "sent": "Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement.",
      "score": -0.9042
    }
  ],
  "forward_snippets": [
    "threat and the global response thereto; \u2022 uncertainties related to our efforts to develop, manufacture, and distribute potential treatments for COVID-19; \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and outcome of acquisitions and business development transactions and related integration costs; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property; \u2022 changes in patent law or regulations related to data package exclusivity; \u2022 competitive developments affecting current products and our pipeline; \u2022 market uptake of recently launched products; \u2022 information technology system inadequacies, breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; \u2022 unexpected safety or efficacy concerns associated with our products; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions relating to our facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 regulatory changes or other developments; \u2022 regulatory actions regarding currently marketed products; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; \u2022 devaluations in foreign currency exchange rates, changes in interest rates, and inflation; \u2022 changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; \u2022 asset impairments and restructuring charges; \u2022 the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions; \u2022 changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and \u2022 regulatory compliance problems or government investigations.",
    "As a result of these agreements, we will record a charge of approximately $ 335 million to acquired IPR&D and development milestones in the second quarter of 2022.",
    "The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss) The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows: Three Months Ended March 31, 2022 2021 Net investment hedges: Foreign currency-denominated notes $ 54.4 $ 207.7 Cross-currency interest rate swaps 10.8 150.6 Cash flow hedges: Forward-starting interest rate swaps 122.5 295.1 Cross-currency interest rate swaps 17.1 26.3 During the next 12\u00a0months, we expect to reclassify $ 16.5 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other\u2013net, (income) expense.",
    "As of March\u00a031, 2022, we had approximately $ 843 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.",
    "As of March\u00a031, 2022, we had approximately $ 843 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.",
    "As of March\u00a031, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities."
  ]
}